Amgen / PHRMA / 7GeneLogic Inc. / DIA / GlaxoSmithKline / Harty LC / PWG / Millennium Pharmaceuticals / /
Country
United States / /
Currency
USD / / /
Event
FDA Phase / Person Communication and Meetings / /
Facility
National Cancer Institute / Hall ST / /
IndustryTerm
Cancer Treatment / therapy for colon cancer / possible solutions / gene products / treatment of breast cancer / receptor binding site / advance online publication / treatment of HER2 positive metastatic breast cancer / /
MarketIndex
SET 50 / /
MedicalCondition
responsive and nonresponsive tumor / II colon cancer / J Cancer / colon cancer / pretreatment tumor / non-small-cell lung cancer / breast / colon and lung adenocarcinoma / breast cancer / breast adenocarcinoma / adenocarcinoma / cancers / tumor / metastatic adenocarcinoma / squamous cell carcinoma / HER2 positive metastatic breast cancer / cancer / colon adenocarcinoma / tumors / disease / lung tumors / malignant disease / lung cancer / cytokine release syndrome / /
MedicalTreatment
chemotherapy / /
Organization
FDA office of Biostatistics / National Cancer Institute / Division of Cancer Treatment and Diagnosis / 4FDA Center / 5FDA Center for Devices and Radiological Health / office of Pharmacoepidemiology and Statistical Science / Audience / FDA / Center for Drug Evaluation and Research / /
Person
Ann Oncol / Simon R. Adaptive / Gene Ontology / Simon R. Diagnostic / /
The Pharmacogenomics Journal (2006), 1–6 & 2006 Nature Publishing Group All rights reserved 1470-269X/06 $30.00 www.nature.com/tpj MEETING REPORT